Compare ProShares Ultra Silver ETF (AGQ) vs 10X Genomics Inc (TXG) Price & Performance

AGQ, a leveraged silver ETF, trades at $81.11, down 0.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights volatility, with articles noting a 9.39% surge on silver rallies but structural decay risks from daily-reset leverage. Financial ratios are unavailable as AGQ is an ETF tracking silver futures, not a company with fundamentals.

The outlook hinges on silver price momentum, offering amplified gains but high risk from leverage decay and silver volatility. Key risks include underperformance versus unlevered ETFs and sharp declines during silver sell-offs, as seen in a 16% drop in June 2026. Investors should weigh silver's bullish trend against ETF-specific drawbacks.

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.